Abstract
Severe mental illness (SMI) and co-occurring substance use disorders (SUDs) continue to pose a major global health challenge, contributing to high rates of mortality, disability, and economic strain. Ibogaine, a naturally occurring psychoactive compound derived from the Tabernanthe iboga plant, has shown promise in easing withdrawal symptoms, reducing cravings, and improving psychiatric symptoms linked to addiction. While early observational studies and a growing number of clinical trials are encouraging, concerns about safety—particularly its impact on heart function, such as QT interval prolongation and the risk of life-threatening arrhythmias—have limited its broader clinical use. Moving forward, key research priorities include conducting large-scale randomized controlled trials with personalized dosing strategies, developing safer synthetic alternatives, investigating the drug’s underlying neurobiological effects, and tracking long-term outcomes. Closing these gaps is crucial to fully understand and safely harness ibogaine’s potential for treating SMI and SUDs.
Keywords
Ibogaine
Prevention
Psychopharmacology
Dear Editor,
Severe mental illness (SMI)—including schizophrenia, bipolar disorder, and major depressive disorder—affects approximately 4–7 % of adults globally and is linked to a 10–20-year reduction in life expectancy due to both direct (e.g., suicide) and indirect (e.g., cardiovascular disease) causes [1], [2]. In 2019, mental and substance use disorders accounted for 14.6 % of global years lived with disability (YLDs) [3], and the cumulative economic impact of mental illness is projected to reach $16 trillion between 2010 and 2030 [4]. Comorbid substance use disorders (SUDs) dramatically worsen clinical outcomes in individuals with SMI, contributing to heightened suicide risk, greater treatment resistance, and higher rates of hospitalization and incarceration [5]. Despite the burden, up to 85 % of individuals in low- and middle-income countries (LMICs) receive no mental health treatment at all [6]. These alarming statistics point to an urgent unmet need for innovative, scalable, and effective treatment strategies that address both SMI and co-occurring SUDs. Recently, ibogaine [7], [8] has garnered increasing attention as a potential breakthrough therapy for individuals suffering from severe mental illness (SMI) and co-occurring substance use disorders (SUDs). Ibogaine is a naturally occurring indole alkaloid derived from the root bark of Tabernanthe iboga, a perennial shrub native to Central and West Africa. Traditionally, it has been used for centuries in the Bwiti spiritual practices of the Fang people in Gabon, Cameroon, and the Republic of Congo. In these ceremonial contexts, ibogaine is administered in high doses during initiation rites and healing rituals, believed to facilitate psychological insight, emotional catharsis, and spiritual guidance [7], [8].
History of Ibogaine
Western interest in ibogaine began in the early 20th century when it was marketed in France as a stimulant called Lambarène. Its anti-addictive properties were discovered unexpectedly in the 1960s when American heroin user Howard Lotsof reported that a single dose of ibogaine led to an abrupt and sustained cessation of opioid withdrawal and cravings [9]. Subsequent informal case reports and preclinical studies supported this anecdotal evidence, increasing renewed scientific interest in its potential as a treatment for addiction and psychiatric disorders.
Clinical and observational evidence
Although large-scale clinical trials remain limited, early findings suggest ibogaine and its metabolite, noribogaine, may attenuate withdrawal symptoms, reduce cravings, and improve mood and trauma-related symptoms, particularly in opioid and stimulant use disorders [10]. Noribogaine, which has a longer half-life and less intense psychoactive effects, may contribute to ibogaine’s prolonged therapeutic window [11].
Two double-blind, placebo-controlled trials—one in opioid-dependent individuals and another in cocaine users—reported modest reductions in dependence symptoms, although both were underpowered and inconclusive due to small sample sizes and methodological limitations [12]. In contrast, several observational studies and case series have reported more encouraging outcomes. For example, in a 12-month follow-up of patients undergoing ibogaine treatment, participants showed significant reductions in depressive symptoms and drug use, although the study also reported a treatment-related death, highlighting the need for medical oversight [13].
A retrospective survey of 88 individuals treated with ibogaine in Mexico found that 54 % remained abstinent from opioids for six months or more, and 30 % reported complete long-term abstinence [14]. A qualitative study involving 73 individuals documented long-lasting psychological benefits such as enhanced emotional regulation, increased meaning in life, and greater authenticity, suggesting ibogaine’s potential role in improving psychological well-being beyond substance use cessation [15].
Prevalence and unregulated use
Koenig and Hilber note that “dozens of clinics worldwide” currently offer ibogaine treatment, primarily for SUDs, across both licensed and unregulated settings [16]. As of 2006, over 3400 individuals had reportedly received ibogaine therapy, with the number likely far higher today [7]. These clinics operate across diverse jurisdictions—including Mexico, Canada, the Netherlands, South Africa, New Zealand, and Brazil—where legal status varies or remains ambiguous. Despite its Schedule I classification in the United States, underground ibogaine treatments continue to occur in illicit or semi-clinical environments, posing safety risks and legal complications [17].
Safety concerns and pharmacological risks
Ibogaine’s most significant barrier to clinical adoption is its safety profile. The drug is known to prolong the QT interval on electrocardiograms, increasing the risk of fatal arrhythmias such as torsades de pointes [18], [19]. Sudden cardiac deaths have been reported in individuals undergoing ibogaine therapy, particularly those with underlying cardiovascular disease, electrolyte imbalances, or concurrent substance use [20], [21]. Ibogaine also exhibits neurotoxicity at high doses in preclinical models, particularly in cerebellar Purkinje cells, and has been associated with adverse neurological events in humans, including ataxia, tremors, and psychosis [22], [23].
The drug’s complex pharmacokinetics—marked by a long half-life and active metabolites—further complicate dosing. Inadequate medical supervision, polypharmacy, and pre-existing health conditions can increase toxicity risk. A review of ibogaine-related fatalities emphasized the need for pre-treatment cardiac screening, inpatient monitoring, and electrolyte management to reduce adverse outcomes [16].
To address these concerns, synthetic analogues such as 18-methoxycoronaridine (18-MC) and tabernanthalog (TBG) are under development. These compounds aim to replicate ibogaine’s anti-addictive and neuroplastic effects without its cardiotoxic or hallucinogenic properties, though human trials are still in early stages [24].
Recent policy developments and regulatory shifts
In response to the growing interest in psychedelic therapies, several U.S. states have introduced policy initiatives supporting ibogaine research. In 2025, Texas launched a $50 million public–private partnership to fund FDA-regulated clinical trials of ibogaine for opioid use disorder (OUD), PTSD, and traumatic brain injury (TBI) [25]. This initiative mandates inpatient treatment settings with cardiac monitoring and emergency protocols, directly addressing the drug’s safety risks. Notably, the state retains intellectual property rights on discoveries made under this program, signaling a strategic investment in psychedelic innovation.
Colorado’s Natural Medicine Health Act allows the creation of licensed “healing centers” for supervised ibogaine administration, emphasizing comprehensive safety protocols, patient screening, and post-treatment monitoring [26]. Additional states—including Arizona, New York, Washington, and Kentucky—have introduced legislation to establish psychedelic research programs, clinical pilot projects, and regulatory boards focused on therapeutic access [27], [28], [29], [30].
Research priorities and path forward
Although preliminary evidence supporting ibogaine’s therapeutic potential is promising, several critical research gaps must be addressed before its integration into mainstream psychiatric and addiction treatment. A primary area of focus is the conduct of randomized controlled trials that incorporate pharmacogenomic considerations, particularly genetic polymorphisms in the CYP2D6 enzyme responsible for ibogaine metabolism, as these variations can significantly influence both efficacy and safety outcomes [31]. Safety remains a major concern, given ibogaine’s propensity to induce cardiac arrhythmias such as QT interval prolongation; therefore, administration should be confined to inpatient settings equipped with continuous ECG monitoring and emergency medical support. Concurrently, ongoing research into the development of safer ibogaine analogues—such as 18-methoxycoronaridine [32] and tabernanthalog [33]—aims to retain therapeutic efficacy while minimizing adverse effects. Further mechanistic studies are also needed to elucidate ibogaine’s modulation of neurotransmitter systems and its role in promoting neuroplasticity, which may inform optimized combination therapies involving pharmacological and psychotherapeutic approaches. Finally, longitudinal studies are essential to evaluate the durability of clinical benefits and to monitor for delayed adverse events, including cognitive impairment, relapse rates, and cardiac complications. Addressing these priorities will be vital for the responsible and safe advancement of ibogaine-based treatments.
